IOmx Therapeutics Appoints Rüdiger Wolff as CFO

iOmx Therapeutics AG, a biopharmaceutical company based in Martinsried, Germany, has announced the appointment of Rüdiger Wolff as their new Chief Financial Officer (CFO) as of October 1, 2026. Wolff joins the company with significant experience in finance leadership, particularly within the life sciences and technology sectors.

Previously, Wolff was Senior Vice President Finance at CureVac, playing a key role in their Nasdaq IPO and overseeing financing activities and organizational transformations. His background also includes finance leadership roles at Woodward GmbH, with responsibilities spanning corporate finance and international business.

Dr. Apollon Papadimitriou, CEO of iOmx, expressed confidence that Wolff's expertise will enhance the company's financial operations and strategy, supporting its growth in developing immunotherapy treatments for resistant solid tumors. Wolff, holding a law degree from the University of Freiburg, aims to bolster iOmx's pipeline and investor relations.